AT7867

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AT7867

CAS No. : 857531-00-1

MCE 国际站：AT7867

产品活性：AT7867 是一种 ATP 竞争性的 Akt1/Akt2/Akt3 和 p70S6K/PKA 抑制剂，IC₅₀ 分别为 32 nM/17 nM/47 nM 和 85 nM/20 nM。

研究领域：PI3K/Akt/mTOR  |  Stem Cell/Wnt  |  MAPK/ERK Pathway

作用靶点：Akt  |  PKA  |  Ribosomal S6 Kinase (RSK)

In Vitro: The inhibition of AKT2 by AT7867 is shown to be ATP-competitive with a K_i of 18nM. AT7867 also displays potent activity against the structurally related AGC kinases p70S6K and PKA, but shows a clear window of selectivity against kinases from other kinase sub-families. In vitro growth inhibition studies show that AT7867 blocks proliferation in a number of human cancer cell lines. AT7867 appears to be most potent at inhibiting proliferation in MES-SA uterine, MDA-MB-468 and MCF-7 breast, and HCT116 and HT29 colon lines (IC₅₀ values range from 0.9-3 μM), and least effective in the two prostate lines tested (IC₅₀ values range from 10-12 μM) .

In Vivo: In vivo: Following oral administration at 20 mg/kg, the elimination of AT7867 from plasma appears to be similar to that observed after i.v. administration. Plasma levels of AT7867 remain above 0.5 μM for at least 6 hours following an oral dose of 20 mg/kg. Assuming linear pharmacokinetics following i.v. administration, the bioavailability by the oral route is calculated to be 44%. In vivo pharmacodynamic (PD) biomarker studies are therefore performed with this model. Following pharmacokinetic and tolerability studies, doses of AT7867 (90 mg/kg p.o. or 20 mg/kg i.p.) are administered to athymic mice bearing MES-SA tumors and the phosphorylation status of GSK3β and S6RP in tumors is monitored over time. Clear inhibition of phosphorylation of the two markers of pathway activity is seen at 2 and 6 hours following treatment with AT7867. By 24 hours, total levels of both GSK3β and S6RP are greatly reduced.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Targeted Diversity Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Serine/Threonine Kinase Inhibitor Library  |  Staurosporine  |  Deferoxamine mesylate  |  MK-2206 dihydrochloride  |  SC79  |  Yoda 1  |  Bucladesine sodium  |  Afatinib  |  Capivasertib  |  H-89 dihydrochloride  |  8-Bromo-cAMP sodium salt  |  Ipatasertib  |  Honokiol  |  Chloramphenicol  |  Fasudil Hydrochloride  |  Oridonin  |  AKT inhibitor VIII  |  Artemisinin  |  Isoginkgetin  |  GSK-690693  |  BI-D1870  |  α-Linolenic acid  |  Guggulsterone  |  Recilisib  |  Scutellarin  |  Miransertib  |  PF-4708671  |  Carnosol  |  Perifosine  |  Afuresertib  |  K-252a

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds